Commentary | Published:

The best of times, the worst of times for psychiatric disease

Nature Neuroscience volume 15, pages 811812 (2012) | Download Citation

As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Acknowledgements

Support from the US National Institutes of Health (grant 5R13MH091947 to M.K.) and the Martinos family is gratefully acknowledged.

Author information

Affiliations

  1. Department of Psychiatry at Columbia University Medical Center, New York, New York, USA.

    • Maria Karayiorgou
  2. The Wellcome Trust Centre for Human Genetics at Oxford University, Oxford, UK.

    • Jonathan Flint
  3. Department of Physiology and Cellular Biophysics, and Department of Neuroscience at Columbia University Medical Center, New York, New York, USA.

    • Joseph A Gogos
  4. Department of Psychiatry and Behavioral Sciences at Stanford University, Stanford, California, USA.

    • Robert C Malenka
  5. Laboratory of Neural Circuits and Behavior and the Howard Hughes Medical Institute, Rockefeller University, New York, New York, USA.

    • Cornelia I Bargmann
  6. MIT Media Lab, McGovern Institute, Department of Brain and Cognitive Sciences and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Edward S Boyden
  7. Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.

    • Edward T Bullmore
  8. GlaxoSmithKline Clinical Unit Cambridge, Cambridge, UK.

    • Edward T Bullmore
  9. Yerkes National Primates Research Center and Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.

    • Anthony W Chan
  10. Emeritus Professor, Emory University, Atlanta, Georgia, USA.

    • Michael Davis
  11. Department of Bioengineering, Department of Psychiatry and Behavioral Sciences, Howard Hughes Medical Institute, Stanford University, Stanford, California, USA.

    • Karl Deisseroth
  12. Department of Neurobiology, Stanford University, Stanford, California, USA.

    • Ricardo E Dolmetch
  13. Allen Institute for Brain Science, Seattle, Washington, USA.

    • Ricardo E Dolmetch
  14. Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts, USA.

    • Kevin Eggan
  15. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Center for Neurobehavioral Genetics, University of California at Los Angeles, Los Angeles, California, USA.

    • Scott C Fears
    •  & Nelson B Freimer
  16. Neurogenetics Program, Department of Neurology, Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.

    • Daniel H Geschwind
  17. New York State Psychiatric Institute, Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.

    • Joshua Gordon
  18. Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington, USA.

    • Debbie A Nickerson
  19. Institute of Interdisciplinary Research at the University of Brussels Medical School, Brussels, Belgium.

    • Pierre Vanderhaeghen
  20. Department of Neuroscience, Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, Columbia University Medical Center, New York, New York, USA.

    • Richard Axel
    •  & Charles S Zuker
  21. Simons Foundation, Autism Research Initiative, New York, New York, USA.

    • Gerald D Fischbach

Consortia

  1. the Genetic and Neural Complexity in Psychiatry 2011 Working Group

    A complete list of authors and affiliations appears at the end of this paper.

Authors

  1. Search for Maria Karayiorgou in:

  2. Search for Jonathan Flint in:

  3. Search for Joseph A Gogos in:

  4. Search for Robert C Malenka in:

Competing interests

Edward Bullmore is employed half-time by University of Cambridge and half-time by GlaxoSmithKline and is a stockholder in GlaxoSmithKline.

Corresponding author

Correspondence to Maria Karayiorgou.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nn.3115

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing